Cargando…
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive t...
Autores principales: | Kounatidou, Evangelia, Nakjang, Sirintra, McCracken, Stuart R C, Dehm, Scott M, Robson, Craig N, Jones, Dominic, Gaughan, Luke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582326/ https://www.ncbi.nlm.nih.gov/pubmed/31006810 http://dx.doi.org/10.1093/nar/gkz286 |
Ejemplares similares
-
IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway
por: Bainbridge, Alex, et al.
Publicado: (2020) -
Identification of a novel K311 ubiquitination site critical for androgen receptor transcriptional activity
por: McClurg, Urszula L., et al.
Publicado: (2017) -
Regulation of the androgen receptor by SET9-mediated methylation
por: Gaughan, Luke, et al.
Publicado: (2011) -
The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer
por: Wade, Mark A., et al.
Publicado: (2015) -
Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies
por: Chan, Siu Chiu, et al.
Publicado: (2015)